Home >> Research Area >>Cell Cycle/Checkpoint>>Cyclin-Dependent Kinases>> PD 0332991 (Palbociclib) HCl

PD 0332991 (Palbociclib) HCl

CDK4/6 inhibitor,highly selective CAS# 827022-32-2

PD 0332991 (Palbociclib) HCl

Catalog No. BCC3680----Order now to get a substantial discount!

Product Name & Size Price Stock
PD 0332991 (Palbociclib) HCl: 5mg $81 In Stock
PD 0332991 (Palbociclib) HCl: 10mg Please Inquire In Stock
PD 0332991 (Palbociclib) HCl: 20mg Please Inquire Please Inquire
PD 0332991 (Palbociclib) HCl: 50mg Please Inquire Please Inquire
PD 0332991 (Palbociclib) HCl: 100mg Please Inquire Please Inquire
PD 0332991 (Palbociclib) HCl: 200mg Please Inquire Please Inquire
PD 0332991 (Palbociclib) HCl: 500mg Please Inquire Please Inquire
PD 0332991 (Palbociclib) HCl: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of PD 0332991 (Palbociclib) HCl

Number of papers citing our products

Chemical structure

PD 0332991 (Palbociclib) HCl

3D structure

Chemical Properties of PD 0332991 (Palbociclib) HCl

Cas No. 827022-32-2 SDF Download SDF
PubChem ID 11431660 Appearance Powder
Formula C24H30ClN7O2 M.Wt 483.99
Type of Compound N/A Storage Desiccate at -20°C
Synonyms PD 0332991 hydrochloride
Solubility DMSO : 5.4 mg/mL (11.16 mM; Need ultrasonic)
H2O : 4.9 mg/mL (10.12 mM; Need ultrasonic and warming)
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;hydrochloride
SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl
Standard InChIKey STEQOHNDWONVIF-UHFFFAOYSA-N
Standard InChI InChI=1S/C24H29N7O2.ClH/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32;/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29);1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of PD 0332991 (Palbociclib) HCl

DescriptionPalbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM.
TargetsCDK4/cyclin D1CDK6/cyclin D2    
IC5011 nM16 nM    

Protocol

Cell experiment: [1]

Cell lines

MDA-MB-453 cells

Preparation method

The solubility of this compound in DMSO is <10 mm. general tips for obtaining a higher concentration: please warm the tube at 37 °c 10 minutes and>

Reacting condition

80 nM, 24 hours

Applications

MDA-MB-453 breast carcinoma cells exposed to varying concentrations of PD 0332991 for 24 hours showed a significant increase in the percentage of cells in G1 in the presence of as little as 0.04 μmol/L PD 0332991 with a concomitant decline in other phases of the cell cycle. Maximum effects were attained at 0.08 μmol/L and an exclusive G1 arrest was maintained even at concentrations as high as 10 μmol/L, consistent with the complete absence of any other effects on the cell cycle.

Animal experiment: [1]

Animal models

Mice bearing Colo-205 colon carcinoma xenografts

Dosage form

Oral administration, 150 or 75 mg/kg, daily for 14 days

Application

Administration of PD 0332991 produced rapid tumor regressions and a corresponding tumor growth delay of about 50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay was obtained indicating a 90% inhibition of tumor growth rate.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Fry D W, Harvey P J, Keller P R, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular cancer therapeutics, 2004, 3(11): 1427-1438.

PD 0332991 (Palbociclib) HCl Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

PD 0332991 (Palbociclib) HCl Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of PD 0332991 (Palbociclib) HCl

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0662 mL 10.3308 mL 20.6616 mL 41.3232 mL 51.654 mL
5 mM 0.4132 mL 2.0662 mL 4.1323 mL 8.2646 mL 10.3308 mL
10 mM 0.2066 mL 1.0331 mL 2.0662 mL 4.1323 mL 5.1654 mL
50 mM 0.0413 mL 0.2066 mL 0.4132 mL 0.8265 mL 1.0331 mL
100 mM 0.0207 mL 0.1033 mL 0.2066 mL 0.4132 mL 0.5165 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on PD 0332991 (Palbociclib) HCl

PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].

PD-0332991 is a highly specific inhibitor of CDK4/6. It is a potent anti-proliferative agent against Rb-positive tumor cells in vitro, subsequently inducing an exclusive G1 arrest. It has been reported to prevent tumor growth in disseminated human myeloma xenografts and induce G1 arrest in primary bone marrow cells [2].

PD-0332991 is also studied in breast cancer. It causes growth inhibition of ER-positive cell lines and 10/16 HER2-amplified cell lines. 100nM PD-0332991 can inhibit the phosphorylation of Rb in three more sensitive cell lines, resulting in prevention of cell cycle progression [2].

References:
[1] Ivan Diaz-Padilla, Lillian L. Siu and Ignacio Duran. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs. 2009, 27: 586–594.
[2] Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los and Dennis J Slamon. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research. 2009, 11: R77.

Featured Products
New Products
 

Description

Palbociclib hydrochloride is a highly selective CDK4/6 inhibitor with IC50s of 11 nM and 16 nM, respectively. Palbociclib hydrochloride has the potential for ER-positive and HER2-negative breast cancer research.

Keywords:

PD 0332991 (Palbociclib) HCl,827022-32-2,PD 0332991 hydrochloride,Natural Products,Cyclin-Dependent Kinases, buy PD 0332991 (Palbociclib) HCl , PD 0332991 (Palbociclib) HCl supplier , purchase PD 0332991 (Palbociclib) HCl , PD 0332991 (Palbociclib) HCl cost , PD 0332991 (Palbociclib) HCl manufacturer , order PD 0332991 (Palbociclib) HCl , high purity PD 0332991 (Palbociclib) HCl

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: